Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CASCADE: Effect of tezepelumab on airway inflammation in adults with inadequately controlled asthma
2018-002069-21Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Aug 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in asthma and severe asthma comparing Tezepelumab with Placebo (2 arms). Primary endpoint: Change from baseline in airway submucosal inflammatory cells. Started Aug 2018; status: completed.
02
Drugs
03
Conditions
asthmasevere asthma
Beyond the preview
Go deeper on 2018-002069-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002069-21.